Docetaxel-Induced Peripheral Neuropathy in Breast Cancer Patients Treated with Adjuvant or Neo-Adjuvant Chemotherapy

Hui Lin Cheng; Alex Molassiotis; Anthony Kwun To Leung; Kam Hung Wong

doi:10.1159/000507843

Docetaxel-Induced Peripheral Neuropathy in Breast Cancer Patients Treated with Adjuvant or Neo-Adjuvant Chemotherapy

Hui Lin Cheng, Alex Molassiotis, Anthony Kwun To Leung, Kam Hung Wong

Research output: Journal article publication › Journal article › Academic research › peer-review

6 Citations (Scopus)

Abstract

Background: Docetaxel-induced peripheral neuropathy (PN) is typically manifested as sensory and motor neuropathy. This study aimed to investigate the incidence, duration, and risk factors of sensory and motor PN and their impact on health-related quality of life (HRQOL) among breast cancer (BC) patients during the first year since starting docetaxel-based chemotherapy.

Methods: We reported a secondary analysis of longitudinal data on docetaxel-induced PN and HRQOL among 127 BC patients.

Results: Cumulative incidence rates of motor and sensory PN were 31.5 and 21.3%, while the median durations of motor and sensory PN were 6 and 13 weeks. A consistently significant risk factor for both PNs was a cumulative docetaxel dose of >300 mg/m2. A significant interaction between sensory PN and time was found for physical and social functioning, while a significant motor PN and time interaction effect was identified for physical functioning only.

Conclusions: Motor PN was more common than sensory PN in BC patients treated with docetaxel. Both types of PN had a significant impact on physical functioning.

Original language	English
Pages (from-to)	269-275
Number of pages	7
Journal	Breast Care
Volume	16
Issue number	3
DOIs	https://doi.org/10.1159/000507843
Publication status	Published - 1 Jun 2021

Keywords

Breast cancer
Chemotherapy
Docetaxel
Health-related quality of life
Peripheral neuropathy

ASJC Scopus subject areas

Surgery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

More information

10.1159/000507843

Cite this

@article{5badc75a25004faca6108c56c96bd42b,

title = "Docetaxel-Induced Peripheral Neuropathy in Breast Cancer Patients Treated with Adjuvant or Neo-Adjuvant Chemotherapy",

abstract = "Background: Docetaxel-induced peripheral neuropathy (PN) is typically manifested as sensory and motor neuropathy. This study aimed to investigate the incidence, duration, and risk factors of sensory and motor PN and their impact on health-related quality of life (HRQOL) among breast cancer (BC) patients during the first year since starting docetaxel-based chemotherapy. Methods: We reported a secondary analysis of longitudinal data on docetaxel-induced PN and HRQOL among 127 BC patients. Results: Cumulative incidence rates of motor and sensory PN were 31.5 and 21.3%, while the median durations of motor and sensory PN were 6 and 13 weeks. A consistently significant risk factor for both PNs was a cumulative docetaxel dose of >300 mg/m2. A significant interaction between sensory PN and time was found for physical and social functioning, while a significant motor PN and time interaction effect was identified for physical functioning only. Conclusions: Motor PN was more common than sensory PN in BC patients treated with docetaxel. Both types of PN had a significant impact on physical functioning. ",

keywords = "Breast cancer, Chemotherapy, Docetaxel, Health-related quality of life, Peripheral neuropathy",

author = "Cheng, {Hui Lin} and Alex Molassiotis and Leung, {Anthony Kwun To} and Wong, {Kam Hung}",

note = "Funding Information: This study was funded by Departmental General Research Funding of School of Nursing in the Hong Kong Polytechnic University. Publisher Copyright: {\textcopyright} 2020 S. Karger AG, Basel. Copyright: All rights reserved.",

year = "2021",

month = jun,

day = "1",

doi = "10.1159/000507843",

language = "English",

volume = "16",

pages = "269--275",

journal = "Breast Care",

issn = "1661-3791",

publisher = "S. Karger AG",

number = "3",

}

TY - JOUR

T1 - Docetaxel-Induced Peripheral Neuropathy in Breast Cancer Patients Treated with Adjuvant or Neo-Adjuvant Chemotherapy

AU - Cheng, Hui Lin

AU - Molassiotis, Alex

AU - Leung, Anthony Kwun To

AU - Wong, Kam Hung

N1 - Funding Information: This study was funded by Departmental General Research Funding of School of Nursing in the Hong Kong Polytechnic University. Publisher Copyright: © 2020 S. Karger AG, Basel. Copyright: All rights reserved.

PY - 2021/6/1

Y1 - 2021/6/1

N2 - Background: Docetaxel-induced peripheral neuropathy (PN) is typically manifested as sensory and motor neuropathy. This study aimed to investigate the incidence, duration, and risk factors of sensory and motor PN and their impact on health-related quality of life (HRQOL) among breast cancer (BC) patients during the first year since starting docetaxel-based chemotherapy. Methods: We reported a secondary analysis of longitudinal data on docetaxel-induced PN and HRQOL among 127 BC patients. Results: Cumulative incidence rates of motor and sensory PN were 31.5 and 21.3%, while the median durations of motor and sensory PN were 6 and 13 weeks. A consistently significant risk factor for both PNs was a cumulative docetaxel dose of >300 mg/m2. A significant interaction between sensory PN and time was found for physical and social functioning, while a significant motor PN and time interaction effect was identified for physical functioning only. Conclusions: Motor PN was more common than sensory PN in BC patients treated with docetaxel. Both types of PN had a significant impact on physical functioning.

AB - Background: Docetaxel-induced peripheral neuropathy (PN) is typically manifested as sensory and motor neuropathy. This study aimed to investigate the incidence, duration, and risk factors of sensory and motor PN and their impact on health-related quality of life (HRQOL) among breast cancer (BC) patients during the first year since starting docetaxel-based chemotherapy. Methods: We reported a secondary analysis of longitudinal data on docetaxel-induced PN and HRQOL among 127 BC patients. Results: Cumulative incidence rates of motor and sensory PN were 31.5 and 21.3%, while the median durations of motor and sensory PN were 6 and 13 weeks. A consistently significant risk factor for both PNs was a cumulative docetaxel dose of >300 mg/m2. A significant interaction between sensory PN and time was found for physical and social functioning, while a significant motor PN and time interaction effect was identified for physical functioning only. Conclusions: Motor PN was more common than sensory PN in BC patients treated with docetaxel. Both types of PN had a significant impact on physical functioning.

KW - Breast cancer

KW - Chemotherapy

KW - Docetaxel

KW - Health-related quality of life

KW - Peripheral neuropathy

UR - http://www.scopus.com/inward/record.url?scp=85087524793&partnerID=8YFLogxK

U2 - 10.1159/000507843

DO - 10.1159/000507843

M3 - Journal article

AN - SCOPUS:85087524793

SN - 1661-3791

VL - 16

SP - 269

EP - 275

JO - Breast Care

JF - Breast Care

IS - 3

ER -

Docetaxel-Induced Peripheral Neuropathy in Breast Cancer Patients Treated with Adjuvant or Neo-Adjuvant Chemotherapy

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

More information

Other files and links

Fingerprint

Cite this